Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 347

1.

A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.

Du Z, Weinhold N, Song GC, Rand KA, Van Den Berg DJ, Hwang AE, Sheng X, Hom V, Ailawadhi S, Nooka AK, Singhal S, Pawlish K, Peters ES, Bock C, Mohrbacher A, Stram A, Berndt SI, Blot WJ, Casey G, Stevens VL, Kittles R, Goodman PJ, Diver WR, Hennis A, Nemesure B, Klein EA, Rybicki BA, Stanford JL, Witte JS, Signorello L, John EM, Bernstein L, Stroup AM, Stephens OW, Zangari M, Van Rhee F, Olshan A, Zheng W, Hu JJ, Ziegler R, Nyante SJ, Ingles SA, Press MF, Carpten JD, Chanock SJ, Mehta J, Colditz GA, Wolf J, Martin TG, Tomasson M, Fiala MA, Terebelo H, Janakiraman N, Kolonel L, Anderson KC, Le Marchand L, Auclair D, Chiu BC, Ziv E, Stram D, Vij R, Bernal-Mizrachi L, Morgan GJ, Zonder JA, Huff CA, Lonial S, Orlowski RZ, Conti DV, Haiman CA, Cozen W.

Blood Adv. 2020 Jan 14;4(1):181-190. doi: 10.1182/bloodadvances.2019000491.

2.

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.

Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, Abdallah AO, Callander N, Lendvai N, Sborov D, Suvannasankha A, Weisel K, Karlin L, Libby E, Arnulf B, Facon T, Hulin C, Kortüm KM, Rodríguez-Otero P, Usmani SZ, Hari P, Baz R, Quach H, Moreau P, Voorhees PM, Gupta I, Hoos A, Zhi E, Baron J, Piontek T, Lewis E, Jewell RC, Dettman EJ, Popat R, Esposti SD, Opalinska J, Richardson P, Cohen AD.

Lancet Oncol. 2019 Dec 16. pii: S1470-2045(19)30788-0. doi: 10.1016/S1470-2045(19)30788-0. [Epub ahead of print]

PMID:
31859245
3.

Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone.

Schmidt TM, Barwick BG, Joseph N, Heffner LT, Hofmeister CC, Bernal L, Dhodapkar MV, Gupta VA, Jaye DL, Wu J, Goyal S, Chen Z, Boise LH, Lonial S, Nooka AK, Kaufman JL.

Blood Cancer J. 2019 Nov 25;9(12):94. doi: 10.1038/s41408-019-0254-0.

4.

Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma.

Lonial S, Jacobus S, Fonseca R, Weiss M, Kumar S, Orlowski RZ, Kaufman JL, Yacoub AM, Buadi FK, O'Brien T, Matous JV, Anderson DM, Emmons RV, Mahindra A, Wagner LI, Dhodapkar MV, Rajkumar SV.

J Clin Oncol. 2019 Oct 25:JCO1901740. doi: 10.1200/JCO.19.01740. [Epub ahead of print]

PMID:
31652094
5.

γ-6-Phosphogluconolactone, a Byproduct of the Oxidative Pentose Phosphate Pathway, Contributes to AMPK Activation through Inhibition of PP2A.

Gao X, Zhao L, Liu S, Li Y, Xia S, Chen D, Wang M, Wu S, Dai Q, Vu H, Zacharias L, DeBerardinis R, Lim E, Metallo C, Boggon TJ, Lonial S, Lin R, Mao H, Pan Y, Shan C, Chen J.

Mol Cell. 2019 Dec 19;76(6):857-871.e9. doi: 10.1016/j.molcel.2019.09.007. Epub 2019 Oct 2.

PMID:
31586547
6.

Hsp90B enhances MAST1-mediated cisplatin resistance by protecting MAST1 from proteosomal degradation.

Pan C, Chun J, Li D, Boese AC, Li J, Kang J, Umano A, Jiang Y, Song L, Magliocca KR, Chen ZG, Saba NF, Shin DM, Owonikoko TK, Lonial S, Jin L, Kang S.

J Clin Invest. 2019 Oct 1;129(10):4110-4123. doi: 10.1172/JCI125963.

7.

Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.

Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, Moreau P, Dingli D, Cole C, Lonial S, Dimopoulos M, Stewart AK, Richter J, Vij R, Tuchman S, Raab MS, Weisel KC, Delforge M, Cornell RF, Kaminetzky D, Hoffman JE, Costa LJ, Parker TL, Levy M, Schreder M, Meuleman N, Frenzel L, Mohty M, Choquet S, Schiller G, Comenzo RL, Engelhardt M, Illmer T, Vlummens P, Doyen C, Facon T, Karlin L, Perrot A, Podar K, Kauffman MG, Shacham S, Li L, Tang S, Picklesimer C, Saint-Martin JR, Crochiere M, Chang H, Parekh S, Landesman Y, Shah J, Richardson PG, Jagannath S.

N Engl J Med. 2019 Aug 22;381(8):727-738. doi: 10.1056/NEJMoa1903455.

PMID:
31433920
8.

SOHO State of the Art Updates and Next Questions: T-Cell-Directed Immune Therapies for Multiple Myeloma: Chimeric Antigen Receptor-Modified T Cells and Bispecific T-Cell-Engaging Agents.

Madduri D, Dhodapkar MV, Lonial S, Jagannath S, Cho HJ.

Clin Lymphoma Myeloma Leuk. 2019 Sep;19(9):537-544. doi: 10.1016/j.clml.2019.08.002. Epub 2019 Aug 7. Review.

PMID:
31427259
9.

Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial.

Usmani SZ, Schjesvold F, Oriol A, Karlin L, Cavo M, Rifkin RM, Yimer HA, LeBlanc R, Takezako N, McCroskey RD, Lim ABM, Suzuki K, Kosugi H, Grigoriadis G, Avivi I, Facon T, Jagannath S, Lonial S, Ghori RU, Farooqui MZH, Marinello P, San-Miguel J; KEYNOTE-185 Investigators.

Lancet Haematol. 2019 Sep;6(9):e448-e458. doi: 10.1016/S2352-3026(19)30109-7. Epub 2019 Jul 18.

PMID:
31327689
10.

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.

Mateos MV, Blacklock H, Schjesvold F, Oriol A, Simpson D, George A, Goldschmidt H, Larocca A, Chanan-Khan A, Sherbenou D, Avivi I, Benyamini N, Iida S, Matsumoto M, Suzuki K, Ribrag V, Usmani SZ, Jagannath S, Ocio EM, Rodriguez-Otero P, San Miguel J, Kher U, Farooqui M, Liao J, Marinello P, Lonial S; KEYNOTE-183 Investigators.

Lancet Haematol. 2019 Sep;6(9):e459-e469. doi: 10.1016/S2352-3026(19)30110-3. Epub 2019 Jul 18.

PMID:
31327687
11.

Registering a CD38 antibody upfront for multiple myeloma.

Hofmeister CC, Nooka A, Kaufman JL, Lonial S.

Lancet. 2019 Jul 6;394(10192):3-4. doi: 10.1016/S0140-6736(19)31250-4. Epub 2019 Jun 3. No abstract available.

PMID:
31171418
12.

International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders.

Hillengass J, Usmani S, Rajkumar SV, Durie BGM, Mateos MV, Lonial S, Joao C, Anderson KC, García-Sanz R, Riva E, Du J, van de Donk N, Berdeja JG, Terpos E, Zamagni E, Kyle RA, San Miguel J, Goldschmidt H, Giralt S, Kumar S, Raje N, Ludwig H, Ocio E, Schots R, Einsele H, Schjesvold F, Chen WM, Abildgaard N, Lipe BC, Dytfeld D, Wirk BM, Drake M, Cavo M, Lahuerta JJ, Lentzsch S.

Lancet Oncol. 2019 Jun;20(6):e302-e312. doi: 10.1016/S1470-2045(19)30309-2. Review. Erratum in: Lancet Oncol. 2019 Jul;20(7):e346.

PMID:
31162104
13.

Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma.

Chari A, Martinez-Lopez J, Mateos MV, Bladé J, Benboubker L, Oriol A, Arnulf B, Rodriguez-Otero P, Pineiro L, Jakubowiak A, de Boer C, Wang J, Clemens PL, Ukropec J, Schecter J, Lonial S, Moreau P.

Blood. 2019 Aug 1;134(5):421-431. doi: 10.1182/blood.2019000722. Epub 2019 May 21.

14.

Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.

Nooka AK, Joseph NS, Kaufman JL, Heffner LT, Gupta VA, Gleason C, Boise LH, Lonial S.

Cancer. 2019 Sep 1;125(17):2991-3000. doi: 10.1002/cncr.32178. Epub 2019 May 15.

PMID:
31090928
15.

Inositol-triphosphate 3-kinase B confers cisplatin resistance by regulating NOX4-dependent redox balance.

Pan C, Jin L, Wang X, Li Y, Chun J, Boese AC, Li D, Kang HB, Zhang G, Zhou L, Chen GZ, Saba NF, Shin DM, Magliocca KR, Owonikoko TK, Mao H, Lonial S, Kang S.

J Clin Invest. 2019 May 13;129(6):2431-2445. doi: 10.1172/JCI124550. eCollection 2019 May 13.

16.

Immunotherapy in Multiple Myeloma: Accelerating on the Path to the Patient.

Ghobrial I, Cruz CH, Garfall A, Shah N, Munshi N, Kaufman J, Boise LH, Morgan G, Adalsteinsson VA, Manier S, Pillai R, Malavasi F, Lonial S.

Clin Lymphoma Myeloma Leuk. 2019 Jun;19(6):332-344. doi: 10.1016/j.clml.2019.02.004. Epub 2019 Feb 20. Review.

PMID:
31023594
17.

Multiple myeloma immunoglobulin lambda translocations portend poor prognosis.

Barwick BG, Neri P, Bahlis NJ, Nooka AK, Dhodapkar MV, Jaye DL, Hofmeister CC, Kaufman JL, Gupta VA, Auclair D, Keats JJ, Lonial S, Vertino PM, Boise LH.

Nat Commun. 2019 Apr 23;10(1):1911. doi: 10.1038/s41467-019-09555-6.

18.

Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy.

Bailur JK, McCachren SS, Doxie DB, Shrestha M, Pendleton K, Nooka AK, Neparidze N, Parker TL, Bar N, Kaufman JL, Hofmeister CC, Boise LH, Lonial S, Kemp ML, Dhodapkar KM, Dhodapkar MV.

JCI Insight. 2019 Apr 23;5. pii: 127807. doi: 10.1172/jci.insight.127807.

19.

Is there still a role for stem cell transplantation in multiple myeloma?

Mina R, Lonial S.

Cancer. 2019 Aug 1;125(15):2534-2543. doi: 10.1002/cncr.32060. Epub 2019 Apr 15. Review.

PMID:
30985927
20.

Daratumumab in multiple myeloma.

Nooka AK, Kaufman JL, Hofmeister CC, Joseph NS, Heffner TL, Gupta VA, Sullivan HC, Neish AS, Dhodapkar MV, Lonial S.

Cancer. 2019 Jul 15;125(14):2364-2382. doi: 10.1002/cncr.32065. Epub 2019 Apr 5. Review.

PMID:
30951198
21.

Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma.

Jagannath S, Heffner LT Jr, Ailawadhi S, Munshi NC, Zimmerman TM, Rosenblatt J, Lonial S, Chanan-Khan A, Ruehle M, Rharbaoui F, Haeder T, Wartenberg-Demand A, Anderson KC.

Clin Lymphoma Myeloma Leuk. 2019 Jun;19(6):372-380. doi: 10.1016/j.clml.2019.02.006. Epub 2019 Feb 21.

PMID:
30930134
22.

Reply to African American patients may or may not have poorer response rates after monoclonal antibody treatment: Overreliance on P values in underpowered studies.

Harvey RD, Zhang C, Lonial S, Kaufman JL, Chen Z.

Cancer. 2019 Mar 28. doi: 10.1002/cncr.32080. [Epub ahead of print] No abstract available.

PMID:
30919409
23.

Mutant and Wild-Type Isocitrate Dehydrogenase 1 Share Enhancing Mechanisms Involving Distinct Tyrosine Kinase Cascades in Cancer.

Chen D, Xia S, Wang M, Lin R, Li Y, Mao H, Aguiar M, Famulare CA, Shih AH, Brennan CW, Gao X, Pan Y, Liu S, Fan J, Jin L, Song L, Zhou A, Mukherjee J, Pieper RO, Mishra A, Peng J, Arellano M, Blum WG, Lonial S, Boggon TJ, Levine RL, Chen J.

Cancer Discov. 2019 Jun;9(6):756-777. doi: 10.1158/2159-8290.CD-18-1040. Epub 2019 Mar 12.

PMID:
30862724
24.

Evaluation of preclinical efficacy of everolimus and pasireotide in thyroid cancer cell lines and xenograft models.

Owonikoko TK, Zhang G, Lallani SB, Chen Z, Martinson DE, Khuri FR, Lonial S, Marcus A, Sun SY.

PLoS One. 2019 Feb 26;14(2):e0206309. doi: 10.1371/journal.pone.0206309. eCollection 2019.

25.

Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance.

Kumar SK, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, Hamadani M, Stewart AK, Hari P, Roy V, Vescio R, Kaufman JL, Berg D, Liao E, Rajkumar SV, Richardson PG.

Leukemia. 2019 Jul;33(7):1736-1746. doi: 10.1038/s41375-019-0384-1. Epub 2019 Jan 29.

26.

Mechanism of Action and Novel IMiD-Based Compounds and Combinations in Multiple Myeloma.

Nooka AK, Lonial S.

Cancer J. 2019 Jan/Feb;25(1):19-31. doi: 10.1097/PPO.0000000000000354.

PMID:
30694856
27.

Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma.

Matulis SM, Gupta VA, Neri P, Bahlis NJ, Maciag P, Leverson JD, Heffner LT Jr, Lonial S, Nooka AK, Kaufman JL, Boise LH.

Leukemia. 2019 May;33(5):1291-1296. doi: 10.1038/s41375-018-0374-8. Epub 2019 Jan 24. No abstract available.

28.

Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study.

Kaufman JL, Mina R, Jakubowiak AJ, Zimmerman TL, Wolf JJ, Lewis C, Gleason C, Sharp C, Martin T, Heffner LT, Nooka AK, Harvey RD, Lonial S.

Blood Cancer J. 2019 Jan 4;9(1):3. doi: 10.1038/s41408-018-0154-8.

29.

High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action.

Adams HC 3rd, Stevenaert F, Krejcik J, Van der Borght K, Smets T, Bald J, Abraham Y, Ceulemans H, Chiu C, Vanhoof G, Usmani SZ, Plesner T, Lonial S, Nijhof I, Lokhorst HM, Mutis T, van de Donk NWCJ, Sasser AK, Casneuf T.

Cytometry A. 2019 Mar;95(3):279-289. doi: 10.1002/cyto.a.23693. Epub 2018 Dec 11.

30.

Safety and survival outcomes for bloodless transplantation in patients with myeloma.

Joseph NS, Kaufman JL, Boise LH, Valla K, Almaula DK, Obidike CO, Langston AA, Waller EK, Khoury HJ, Flowers CR, Graiser M, Heffner LT, Lonial S, Nooka AK.

Cancer. 2019 Jan 15;125(2):185-193. doi: 10.1002/cncr.31677. Epub 2018 Nov 27.

31.

Ixazomib for the treatment of multiple myeloma.

Richardson PG, Zweegman S, O'Donnell EK, Laubach JP, Raje N, Voorhees P, Ferrari RH, Skacel T, Kumar SK, Lonial S.

Expert Opin Pharmacother. 2018 Dec;19(17):1949-1968. doi: 10.1080/14656566.2018.1528229. Epub 2018 Nov 13. Review.

PMID:
30422008
32.

Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma.

Chari A, Lonial S, Mark TM, Krishnan AY, Stockerl-Goldstein KE, Usmani SZ, Londhe A, Etheredge D, Fleming S, Liu B, Ukropec J, Lin TS, Jagannath S, Nooka AK.

Cancer. 2018 Nov 15;124(22):4342-4349. doi: 10.1002/cncr.31706. Epub 2018 Nov 5.

33.

Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents.

Mina R, Joseph NS, Kaufman JL, Gupta VA, Heffner LT, Hofmeister CC, Boise LH, Dhodapkar MV, Gleason C, Nooka AK, Lonial S.

Cancer. 2019 Feb 1;125(3):416-423. doi: 10.1002/cncr.31718. Epub 2018 Oct 17.

PMID:
30332496
34.

Response to therapeutic monoclonal antibodies for multiple myeloma in African Americans versus whites.

Chehab S, Zhang C, Panjic EH, Chen Z, Kaufman JL, Lonial S, Nooka A, Harvey RD.

Cancer. 2018 Nov 15;124(22):4358-4365. doi: 10.1002/cncr.31746. Epub 2018 Oct 10.

35.

Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma.

Richardson PG, Hofmeister CC, Raje NS, Siegel DS, Lonial S, Laubach J, Efebera YA, Vesole DH, Nooka AK, Rosenblatt J, Doss D, Zaki MH, Bensmaine A, Herring J, Li Y, Watkins L, Chen MS, Anderson KC.

Leukemia. 2018 Oct;32(10):2305. doi: 10.1038/s41375-018-0235-5.

36.

Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial.

Dimopoulos MA, Lonial S, Betts KA, Chen C, Zichlin ML, Brun A, Signorovitch JE, Makenbaeva D, Mekan S, Sy O, Weisel K, Richardson PG.

Cancer. 2018 Oct 15;124(20):4032-4043. doi: 10.1002/cncr.31680. Epub 2018 Sep 11.

37.

Lenalidomide and dexamethasone in patients with relapsed multiple myeloma and impaired renal function: PrE1003, a PrECOG study.

Mikhael J, Manola J, Dueck AC, Hayman S, Oettel K, Kanate AS, Lonial S, Rajkumar SV.

Blood Cancer J. 2018 Aug 29;8(9):86. doi: 10.1038/s41408-018-0110-7.

38.

Daratumumab and its use in the treatment of relapsed and/or refractory multiple myeloma.

Chehab S, Panjic EH, Gleason C, Lonial S, Nooka AK.

Future Oncol. 2018 Dec;14(30):3111-3121. doi: 10.2217/fon-2018-0275. Epub 2018 Aug 23. Review.

PMID:
30136602
39.

Co-inhibition of BET and proteasome enhances ER stress and Bim-dependent apoptosis with augmented cancer therapeutic efficacy.

Qian G, Yao W, Zhang S, Bajpai R, Hall WD, Shanmugam M, Lonial S, Sun SY.

Cancer Lett. 2018 Oct 28;435:44-54. doi: 10.1016/j.canlet.2018.07.033. Epub 2018 Jul 29.

PMID:
30059709
40.

MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation.

Jin L, Chun J, Pan C, Li D, Lin R, Alesi GN, Wang X, Kang HB, Song L, Wang D, Zhang G, Fan J, Boggon TJ, Zhou L, Kowalski J, Qu CK, Steuer CE, Chen GZ, Saba NF, Boise LH, Owonikoko TK, Khuri FR, Magliocca KR, Shin DM, Lonial S, Kang S.

Cancer Cell. 2018 Aug 13;34(2):315-330.e7. doi: 10.1016/j.ccell.2018.06.012. Epub 2018 Jul 19.

41.

Myocarditis With Radiotherapy and Immunotherapy in Multiple Myeloma.

Chang A, Nasti TH, Khan MK, Parashar S, Kaufman JL, Boise LH, Lonial S, Ahmed R, Nooka AK.

J Oncol Pract. 2018 Sep;14(9):561-564. doi: 10.1200/JOP.18.00208. Epub 2018 Jul 13. No abstract available.

PMID:
30004825
42.

Managing Infusion Reactions to New Monoclonal Antibodies in Multiple Myeloma: Daratumumab and Elotuzumab.

Nooka AK, Gleason C, Sargeant MO, Walker M, Watson M, Panjic EH, Lonial S.

J Oncol Pract. 2018 Jul;14(7):414-422. doi: 10.1200/JOP.18.00143. Review.

PMID:
29996069
43.

A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis.

Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies F, Rosenthal A, Wang H, Qu P, Hoering A, Samur M, Towfic F, Ortiz M, Flynt E, Yu Z, Yang Z, Rozelle D, Obenauer J, Trotter M, Auclair D, Keats J, Bolli N, Fulciniti M, Szalat R, Moreau P, Durie B, Stewart AK, Goldschmidt H, Raab MS, Einsele H, Sonneveld P, San Miguel J, Lonial S, Jackson GH, Anderson KC, Avet-Loiseau H, Munshi N, Thakurta A, Morgan G.

Leukemia. 2019 Jan;33(1):159-170. doi: 10.1038/s41375-018-0196-8. Epub 2018 Jul 2.

44.

A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma.

San-Miguel JF, Echeveste Gutierrez MA, Špicka I, Mateos MV, Song K, Craig MD, Bladé J, Hájek R, Chen C, Di Bacco A, Estevam J, Gupta N, Byrne C, Lu V, van de Velde H, Lonial S.

Haematologica. 2018 Sep;103(9):1518-1526. doi: 10.3324/haematol.2017.185991. Epub 2018 Jun 28.

45.

Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma.

Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies FE, Rosenthal A, Wang H, Qu P, Hoering A, Samur M, Towfic F, Ortiz M, Flynt E, Yu Z, Yang Z, Rozelle D, Obenauer J, Trotter M, Auclair D, Keats J, Bolli N, Fulciniti M, Szalat R, Moreau P, Durie B, Stewart AK, Goldschmidt H, Raab MS, Einsele H, Sonneveld P, San Miguel J, Lonial S, Jackson GH, Anderson KC, Avet-Loiseau H, Munshi N, Thakurta A, Morgan GJ.

Blood. 2018 Aug 9;132(6):587-597. doi: 10.1182/blood-2018-03-840132. Epub 2018 Jun 8. Erratum in: Blood. 2018 Sep 27;132(13):1461.

46.

Patient-reported outcomes of multiple myeloma patients treated with panobinostat after ≥2 lines of therapy based on the international phase 3, randomized, double-blind, placebo-controlled PANORAMA-1 trial.

Richardson PG, Schlossman RL, Roy AN, Panneerselvam A, Acharyya S, Sopala M, Lonial S.

Br J Haematol. 2018 Jun;181(5):628-636. doi: 10.1111/bjh.15248. Epub 2018 May 17.

PMID:
29774521
47.

The Dietary Supplement Chondroitin-4-Sulfate Exhibits Oncogene-Specific Pro-tumor Effects on BRAF V600E Melanoma Cells.

Lin R, Xia S, Shan C, Chen D, Liu Y, Gao X, Wang M, Kang HB, Pan Y, Liu S, Chung YR, Abdel-Wahab O, Merghoub T, Rossi M, Kudchadkar RR, Lawson DH, Khuri FR, Lonial S, Chen J.

Mol Cell. 2018 Mar 15;69(6):923-937.e8. doi: 10.1016/j.molcel.2018.02.010.

48.

Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma.

van de Donk NWCJ, Casneuf T, Di Cara A, Parren PW, Zweegman S, van Kessel B, Lokhorst HM, Usmani SZ, Lonial S, Richardson PG, Chiu C, Mutis T, Nijhof IS, Sasser AK.

Br J Haematol. 2019 Feb;184(3):475-479. doi: 10.1111/bjh.15122. Epub 2018 Feb 7. No abstract available.

PMID:
29411874
49.

Current developments in immunotherapy in the treatment of multiple myeloma.

Köhler M, Greil C, Hudecek M, Lonial S, Raje N, Wäsch R, Engelhardt M.

Cancer. 2018 May 15;124(10):2075-2085. doi: 10.1002/cncr.31243. Epub 2018 Feb 6. Review.

50.

CD86 regulates myeloma cell survival.

Gavile CM, Barwick BG, Newman S, Neri P, Nooka AK, Lonial S, Lee KP, Boise LH.

Blood Adv. 2017 Nov 16;1(25):2307-2319. doi: 10.1182/bloodadvances.2017011601. eCollection 2017 Nov 28.

Supplemental Content

Loading ...
Support Center